Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Alan P. Venook, Fang-Shu Ou, Heinz-Josef Lenz, Omar Kabbarah, Xueping Qu, Donna Niedzwiecki, Tyler Zemla, Richard M. Goldberg, Howard S. Hochster, Bert H. O‘Neil, Hanna Kelly Sanoff, Robert J. Mayer, Monica M. Bertagnolli, Charles David Blanke, Federico Innocenti

University of California, San Francisco, San Francisco, CA
Mayo Clinic Cancer Center, Rochester, MN
Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Genentech, Inc., San Francisco, CA
Duke University Medical Center, Durham, NC
Mayo Clinic, Rochester, MN
Ohio State University Comprehensive Cancer Center, Columbus, OH
Yale Cancer Center, New Haven, CT
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Dana-Farber Cancer Institute/Partners CancerCare, Boston, MA
Brigham and Women‘s Hospital, Boston, MA
Oregon Health & Science University, Portland, OR
The University of North Carolina at Chapel Hill, Chapel Hill, NC